Haiyi Jiang

Trials

Studies that name Haiyi Jiang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:51 UTC. Open this list on ClinicalTrials.gov

• Ph3
  NCT03703297 · Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

  AstraZeneca · active not recruiting · Small Cell Lung Cancer · study director
• Ph3
  NCT03043872 · Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

  AstraZeneca · active not recruiting · Small Cell Lung Carcinoma Extensive Disease · study director
• Ph2
  NCT02937818 · A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

  AstraZeneca · completed · Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma · study director
• Ph3
  NCT01544179 · A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone

  AstraZeneca · completed · Non-Small Cell Lung Cancer · study director
• Ph4
  NCT01203917 · Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

  AstraZeneca · completed · Caucasian Patients With EGFR Mutation Positive Advanced NSCLC · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 01:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.